TSE:MFC

Manulife Financial (MFC.TO)

57.04
+0.49 (0.87%)
as of Jun 25, 2026, 8:00:00 pm Market Open.
1634 watching
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 28 opinions in the last 12 months.

Manulife Financial (MFC) has garnered mixed opinions from market experts. Many analysts recognize MFC's potential, particularly highlighting its growth in Asia and successful capital generation from legacy businesses. The consensus seems to indicate a solid long-term investment due to its steady dividend yield, with several experts suggesting that patience may be required as the stock navigates short-term fluctuations. Despite some concerns about past performance and market positioning against competitors, the company's strategy and management is viewed positively. Analysts mention the current valuation as reasonable compared to peers, suggesting MFC is a better option for income rather than growth. Overall, there is a cautious optimism about MFC's capabilities and future direction.

consensus icon
Consensus
Hold
valuation icon
Valuation
Fair Value
review icon
Similar
SLF-T
HOLD
The stock is cheap and he holds it in the portfolio. Trades at a low price to book value. Yield 4.5%
COMMENT

This and SLF have been diversifying. MFC is pushing their wealth management business and increasingly from the Asian market. He's gun-shy on MFC. He used to own it.

BUY
Likes the financial sector. It’s been in a tight range. Found support around $22.50. There is good support at $20. Would be a buyer here.
BUY
Average down? Yes, enter it now. MFC trades at 7x earnings and yields over 4% and trades below book value, so it's now at a discount. Their wealth/asset management and Asian business are doing well.
BUY

Long term? He likes MFC, a mainstay for him. MFC has been through a trial over the past 12 months with a legal issue. He likes the 4.6% dividend, which matches the banks, something he was a doubtful about just recently. MFC isn't a bad way to collect yield. It has strong fundamentals. Good long term and he would add to it now. They are growing their dividend.

HOLD

It has been a bit of a disappointment in that it has Asian exposure and has been there for decades, but the yield curve is a real headwind. They have to keep taking charges. He prefers SLF-T. They are good, solid companies, but they need a break on the yield curve.

DON'T BUY
He recently sold it, because MFC broke a trend as interest rates fell and he saw better returns in REITs. MFC's equity division fluctuates with the economy. That said, very long term you can hold this for a long time. But there are better opportunities like the Brookfield REITs.
BUY
Stay in this one. A company you want to hold in a volatile market. Lower interest rates would make this company suffer and this is the fundamental problem for them right now. They need higher rates to fund their actuarial exposure. Buy it here and hold long term. Yield 4.9%
PAST TOP PICK
(A Top Pick Aug 09/18, Down 3%) One of the more diverse names in the insurance space. Exposure to US and Asia. Their results have been fine, and their last quarter was good. You can collect dividends while waiting for the company to get a footing.
DON'T BUY
During low interest rates Low rates are deadly for lifecos which are invested in fixed income and real estate. Don't invest in rate-sensitive stocks.
HOLD
MFC-T vs. Canadian Banks. He considers MFC-T to be a core holding. Low interest rates are a challenge for all financials. MFC-T is cleaning up some assets in the US. They are getting these assets under control. They are still growing in Asia. He thinks low interest rates are priced in to the stock price. (Analysts’ price target is $28.00)
BUY
He sees upside. A large part of the assets are bonds and prices have gone up lately. They are, however, suffering with low yields for new money. New insurance policies should get more expensive. It is a great long term hold and you have to accept the volatility. Things could get softer if rates go to zero.
COMMENT
Great Asian franchise. Problem is the US franchise John Hancock, which dragged down their ROE. Strong asset management in Canada. Nice dividend. Low interest rates not helping. Cleaned up balance sheet. Not paying a lot for the stock.
BUY ON WEAKNESS
They still have some litigation overhang though it's partially resolved. Their Q2 results were fine with minimal difference between core and reporting earnings--good. Book value per share is higher at $22.89, so the stock is trading right under this now. Asian earnings were up 15% year over year, which the market was worried about. The balance sheet is improving. He sees 8% EPS growth. Tt's trading at a very low 6.9x PE 2020. Very cheap with a good dividend. You can add a little on weakness in coming months.
COMMENT
Stuck in a trading range. Short sellers? Wouldn't have considered Manulife being a prime candidate for options selling. He blames interest rates. For insurance company to work, across the globe, you need higher interest rates. The other things is there has been some missteps in the past, did a big financing at the top, issued a lot of shares, they should look at buying back shares. Likes the exposure to China and India. Owns the stock, great company, and continues to hold it. 4% dividend yield.
Showing 361 to 375 of 2,281 entries